血管紧张素Ⅱ1型受体自身抗体与冠脉介入治疗术后再狭窄关系的初步研究  

Autoantibodies against ATe-receptor in patients with restenosis after percutaneous coronary intervention

作　　者：黄燕妮[1,2] 王敬萍[1,2] 马秀瑞[1,2] 冯强[1,2] 杜海萍[1] 

机构地区：[1]山西医科大学第一临床医学院心内科,太原市030001 [2]山西省心血管病医院心脏重症监护室

出　　处：《中国心血管病研究》2012年第2期119-122,共4页Chinese Journal of Cardiovascular Research

摘　　要：目的 探讨抗血管紧张素Ⅱ1型受体自身抗体（AT-AA）与冠脉介入治疗（PCI）术后再狭窄形成的关系。方法选择既往行PCI治疗的冠心病患者67例，根据冠脉造影结果分为再狭窄组（35例）及非再狭窄组（32例）；另选择对照组26例。应用酶联免疫吸附测定（ELISA）技术检测三组患者血清AT1-AA。结果再狭窄组患者血清AT1-AA阳性率高于非再狭窄组（45．7％比21．9％，P〈0．05）及对照组（45．7％比11．5％，P〈0．01）。结论AT1-AA可能参与PCI术后再狭窄发生、发展的病理生理过程。Objective This study will explore the role of autoantibodies against AT1-receptor （AT1-AA） in the development of patients with restenosis after percutaneous coronary intervertion （PCI）. Methods Select 93 hospitalized patients who include control （n=26） and patients with coronary heart disease accepted PCI previously who according to the results of coronary angiography were divided into restenosis（n=35） and no restenosis（n=32）. The epitope of the 2nd extracellular loop of type 1 angiotensin （AT1 receptor were synthesized and used as antigens to screen the autoantibodies against AT1-receptor in the serum of all patients by ELISA. Results Patients with restenosis, the positive rates of autoantibodies against AT1-receptor were higher than without restenosis （45.7% vs 21.9%, P〈0.05） and controls （45.7% vs 11.5%, P〈0.01）. Conclusion Autoantibodies against ATreceptor might play a role in the pathophysiological process of restenosis after PCI.

关 键 词：血管成形术 冠脉再狭窄 受体 血管紧张素Ⅱ1型受体 自身抗体 

分 类 号：R541.4[医药卫生—心血管疾病]